AR033631A1 - 1-oxa-3,9-diaza-espiro[5.5]undecan-2-onas - Google Patents

1-oxa-3,9-diaza-espiro[5.5]undecan-2-onas

Info

Publication number
AR033631A1
AR033631A1 ARP020101705A ARP020101705A AR033631A1 AR 033631 A1 AR033631 A1 AR 033631A1 AR P020101705 A ARP020101705 A AR P020101705A AR P020101705 A ARP020101705 A AR P020101705A AR 033631 A1 AR033631 A1 AR 033631A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
compounds
espiro
onas
undecan
Prior art date
Application number
ARP020101705A
Other languages
English (en)
Spanish (es)
Inventor
Hai-Ying Cai
Michael Patrick Dillon
Guido Galley
Annick Goergler
Sabine Kolczewski
Dawn Marie Muszynski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR033631A1 publication Critical patent/AR033631A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP020101705A 2001-05-14 2002-05-10 1-oxa-3,9-diaza-espiro[5.5]undecan-2-onas AR033631A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111644 2001-05-14

Publications (1)

Publication Number Publication Date
AR033631A1 true AR033631A1 (es) 2003-12-26

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101705A AR033631A1 (es) 2001-05-14 2002-05-10 1-oxa-3,9-diaza-espiro[5.5]undecan-2-onas

Country Status (17)

Country Link
US (1) US6599900B2 (enExample)
EP (1) EP1390372B1 (enExample)
JP (1) JP4056887B2 (enExample)
KR (1) KR100618063B1 (enExample)
CN (1) CN1264847C (enExample)
AR (1) AR033631A1 (enExample)
AT (1) ATE401333T1 (enExample)
AU (1) AU2002342238B2 (enExample)
BR (1) BR0209604A (enExample)
CA (1) CA2447329C (enExample)
DE (1) DE60227657D1 (enExample)
DK (1) DK1390372T3 (enExample)
ES (1) ES2310206T3 (enExample)
MX (1) MXPA03010321A (enExample)
PT (1) PT1390372E (enExample)
WO (1) WO2002092604A1 (enExample)
ZA (1) ZA200308535B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522160A (ja) * 2004-02-10 2007-08-09 エフ．ホフマン−ラ　ロシュ　アーゲー ケモカインｃｃｒ５受容体モジュレーター
RU2007129642A (ru) 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) Таблетки с улучшенным распределением лекарственного вещества
EA012421B1 (ru) * 2005-03-03 2009-10-30 Янссен Фармацевтика Н. В. Замещённые производные оксадиазаспиро[5.5]ундеканона и их применение в качестве антагонистов нейрокинина
KR101388453B1 (ko) 2005-03-08 2014-04-23 얀센 파마슈티카 엔.브이. 뉴로키닌 (ｎｋ１) 길항제로서의디아자-스피로-[４.４]-노난 유도체
US7470684B2 (en) * 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
KR20090127298A (ko) 2007-03-29 2009-12-10 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
BR112018000041A2 (pt) 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
SG11201906417RA (en) 2017-01-20 2019-08-27 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201906427QA (en) 2017-01-23 2019-08-27 Pfizer Heterocyclic spiro compounds as magl inhibitors
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ES2227612T3 (es) * 1995-09-29 2005-04-01 Eli Lilly And Company Compuestos espiro como inhibidores de agregacion plaquetaria dependiente del fibrinogeno.

Also Published As

Publication number Publication date
DE60227657D1 (de) 2008-08-28
JP2004534758A (ja) 2004-11-18
US20030004163A1 (en) 2003-01-02
CN1264847C (zh) 2006-07-19
KR20030094405A (ko) 2003-12-11
EP1390372A1 (en) 2004-02-25
CA2447329A1 (en) 2002-11-21
MXPA03010321A (es) 2004-02-17
CA2447329C (en) 2009-07-28
ES2310206T3 (es) 2009-01-01
ZA200308535B (en) 2005-01-31
AU2002342238B2 (en) 2007-01-25
CN1507449A (zh) 2004-06-23
WO2002092604A1 (en) 2002-11-21
BR0209604A (pt) 2004-03-23
KR100618063B1 (ko) 2006-08-30
DK1390372T3 (da) 2008-09-15
ATE401333T1 (de) 2008-08-15
US6599900B2 (en) 2003-07-29
JP4056887B2 (ja) 2008-03-05
EP1390372B1 (en) 2008-07-16
PT1390372E (pt) 2008-08-25

Similar Documents

Publication Publication Date Title
AR033631A1 (es) 1-oxa-3,9-diaza-espiro[5.5]undecan-2-onas
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
PE20010009A1 (es) Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
ES2184772T3 (es) Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos.
PA8491101A1 (es) Derivados de 4-fenil-piridin.
ECSP034932A (es) Derivados de tetrahidroquinolina
SE0104332D0 (sv) Therapeutic agents
ES2151192T3 (es) Compuestos de quinolina y quinazolina utiles en terapia.
CO5130004A1 (es) 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
PA8575001A1 (es) Fluorobenzamidas como inhibidores de maob
DK0587499T3 (da) Benzopyranforbindelser, fremgangsmåde til deres fremstilling og deres anvendelse som cellebeskyttelsesmidler
ES2141787T3 (es) Derivados de la 1,2,3,4-tetrahidro-9-acridinamina.
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
AR037221A1 (es) Compuestos derivados de piridina, uso de los mismos, un procedimiento para su preparacion y un medicamento que contiene uno o mas de dichos compuestos
IL169257A0 (en) Cycloalkene dicarboxylic acid compounds as anti-infammatory, immunomodulatory and anti-proliferatory agents
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
NO20000737D0 (no) Tetrahydro <gamma>-karboliner
ES2061753T3 (es) (4,5-c)imidazopiridinas substituidas en 5.
AR041898A1 (es) Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales

Legal Events

Date Code Title Description
FB Suspension of granting procedure